Results 201 to 210 of about 38,769 (305)

Ertugliflozin - SGLT2 inhibitor [PDF]

Interní medicína pro praxi, 2019
openaire   +1 more source

Time in range during caloric restriction in type 2 diabetes with obesity

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Introduction To evaluate glycemic changes during caloric restriction with continuous glucose monitoring (CGM)‐derived time in range (TIR) in individuals with type 2 diabetes and obesity. Materials and Methods This 12‐week single‐arm intervention consisted of 6 weeks of home‐delivered meals (800–1,200 kcal/day), followed by 6 weeks of self ...
Jinyoung Kim, Joonyub Lee, Mee Kyoung Kim, Oakkee Hong, Young Na, Su‐Jeong Park, Yoon‐Ju Song, Ki‐Hyun Baek, Ki‐Ho Song, Hyuk‐Sang Kwon   +9 more
wiley   +1 more source

Ferroptosis regulation by SGLT2 inhibitors: mechanisms and clinical benefits in diabetic kidney disease. [PDF]

Front Pharmacol
He S, Wu Z, Li S.
europepmc   +1 more source

Cholesterol accumulation in monocytes is associated with the severity of diabetic complications and the efficacy of glycemic control interventions in patients with type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
This study reveals that monocyte cholesterol accumulation correlates with the severity of diabetic complications and predicts post‐discharge glycemic deterioration. These findings suggest that monocytic cholesterol serves as a novel translational biomarker reflecting ‘metabolic memory’ and therapeutic resistance in patients with type 2 diabetes ...
Hideyuki Okuma, Takahiro Tsutsumi, Asako Miyazaki, Kyoichiro Tsuchiya   +3 more
wiley   +1 more source

Response to SGLT2 inhibitors in heart failure with tricuspid regurgitation: clinical interpretation and future directions. [PDF]

Eur Heart J Cardiovasc Pharmacother
Loutati R, Copeland V, Elimeleh S, Hochstein D, Faierstein K, Milwidsky A, Ben-Zekry S, Segev A, Kuperstein R, Maor E.   +9 more
europepmc   +1 more source

SGLT2 Inhibitors After Myocardial Infarction: Evidence, Mechanisms and Gaps in Knowledge. [PDF]

J Clin Med
Buonpane A, Ciardetti M, Trimarchi G, Scalone G, Coceani MA, Pastormerlo LE, Marchi F, Paradossi U, Berti S, Passino C, De Caterina AR.   +10 more
europepmc   +1 more source

Repurposing SGLT2 inhibitors [PDF]

Nature Reviews Drug Discovery, 2018
openaire   +1 more source

Cardioprotective effects of sodium-glucose cotransporter SGLT2 inhibitors.

Cardiovascular diseases are one of the most common causes of death in both non-diabetic and diabetic patients. Nowadays, a large number of drugs target cardiovascular problems.
Thořová, Markéta
core  

Enavogliflozin Improves Non‐invasive Hepatic Steatosis Indices in Patients With Type 2 Diabetes: A Pooled Analysis of Three Randomised Trials

Diabetes, Obesity and Metabolism, EarlyView.
Min Kyoung Jang, Chang Hee Jung, Han Sol Lee, Areum Lee, Su‐Jin Jeoung, Yong‐Ho Lee, Hae Jin Kim, So Hun Kim, Sung Hoon Yu, Suk Chon, In Kyung Jeong   +10 more
wiley   +1 more source

Sodium–glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial

Journal of Diabetes Investigation, EarlyView.
Combining oral sodium‐glucose cotransporter 2 inhibitors with reduced intravitreal injections of anti‐vascular endothelial growth factor showed potential efficacy for mild diabetic macular edema. ABSTRACT Aims To investigate the potential of sodium–glucose cotransporter 2 inhibitors (SGLT2i) as a less invasive treatment option for mild diabetic macular
Yoko Takatsuna, Ryoichi Ishibashi, Masaya Koshizaka, Tomoaki Tatsumi, Takayuki Baba, Shuichi Yamamoto, Koutaro Yokote   +6 more
wiley   +1 more source